Jazz Pharmaceuticals plc Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Jazz Pharmaceuticals plc (JAZZ) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $164.45 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2022-03-01
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $164.45, a 38.67% increase from fiscal 2020.
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $118.59, a 14.15% decline from fiscal 2019.
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2019 was $138.14, a 4.75% decline from fiscal 2018.
- Jazz Pharmaceuticals plc share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2018 was $145.03, a 5.51% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2021-12-31 | $164.45 10-K · filed 2022-03-01 |
| 2020-12-31 | $118.59 10-K · filed 2021-02-23 |
| 2019-12-31 | $138.14 10-K · filed 2020-02-25 |
| 2018-12-31 | $145.03 10-K · filed 2019-02-26 |
| 2017-12-31 | $137.46 10-K · filed 2018-02-27 |
| 2016-12-31 | $125.80 10-K · filed 2017-02-28 |
| 2015-12-31 | $173.30 10-K · filed 2016-02-23 |
| 2014-12-31 | $160.40 10-K · filed 2015-02-24 |
| 2013-12-31 | $62.46 10-K · filed 2014-02-25 |
| 2012-12-31 | $49.20 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |